FNY Managed Accounts’s Denali Therapeutics DNLI Stock Holding History

FNY Managed Accounts’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,200	Closed	-$34K	–	653
2017 Q4	$34K	Buy	+2,200	New	+$39.5K	0.03%	106

Other funds holding DNLI

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

FNY Managed Accounts's DNLI Position: Q1 2018 in Review

FNY Managed Accounts sold out of Denali Therapeutics (DNLI) in Q1 2018, closing a stake of 2,200 shares — an estimated $34K sold.

FNY Managed Accounts first reported a position in DNLI in Q4 2017 and held it in 1 quarter. The position peaked at $34K in Q4 2017. 58 funds tracked by Wall St. Rank hold DNLI as of Q1 2018.

FNY Managed Accounts reported no remaining Denali Therapeutics position as of Q1 2018 after selling out during the quarter.
FNY Managed Accounts sold 2,200 Denali Therapeutics shares in Q1 2018, an estimated $34K.
FNY Managed Accounts first reported a position in Denali Therapeutics in Q4 2017 and held it in 1 quarter.
FNY Managed Accounts's Denali Therapeutics position peaked at $34K in Q4 2017.
58 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.